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Introduction: The cognitive impact of opioid dependence is rarely measured 
systematically in everyday clinical practice even though both patients and clinicians accept 
that cognitive symptoms often occur in the opioid-dependent population. There are only a 
few publications which utilized computerized neuropsychological tests to assess possible 
impairments of visuospatial memory in opioid-dependent individuals either receiving 
opioid replacement therapy (ORT) or during subsequent short-term abstinence and the 
effects of anxiety and depression.
Methods: We assessed a cohort of 102 participants, comprising i) a stable opioid-
dependent group receiving methadone maintenance treatment (MMT) (n = 22), ii) a stable 
opioid-dependent group receiving buprenorphine (BMT) (n = 20), iii) a current abstinent 
but previously opioid-dependent group (ABS) (n = 8), and iv) a control group who have 
never been dependent on opioids. The Cambridge Neuropsychological Automated Test 
Battery (CANTAB) neuropsychological tasks undertaken by participants included: Delayed 
Matching to Sample (DMS), Pattern Recognition Memory (PRM), Spatial Recognition 
Memory (SRM), and Paired Associate Learning (PAL) tasks. Three clinical measures were 
used to assess the severity of anxiety and depressive illness: Hospital Anxiety Scale-
Hospital Anxiety Depression (HADA)-(HADD), Beck Depression Inventory (BDI), and 
Inventory of Depressive Symptomatology (self-report) (ISD-SR).
Results: The methadone- and buprenorphine-treated groups showed significant 
impairments (p < 0.001) in visuospatial memory tasks but not the abstinent group. 
Impairments in visuospatial memory strongly correlated with higher mood and anxiety 
symptom severity scores (p < 0.001).
Discussion: These results are broadly consistent with previous studies. Uniquely, though, 
here we report a strong relationship between visuospatial memory and depression and 
anxiety scores, which might suggest common illness mechanisms.
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INTRODUCTION
Substance misuse is a chronic condition often characterized by 
remissions and relapses (1). Individuals with a history of long-
term opioid dependence may demonstrate cognitive impairments, 
primarily within the executive functioning domains (2–8).
These impairments have been linked to grey matter reductions 
in the prefrontal cortex, anterior mid-cingulate cortex, and basal 
ganglia (9), brain regions thought responsible for the regulation 
of cravings, pain, and emotional experience. In addition, other 
studies have reported how opioids affect memory, learning, and 
emotional disturbances (2, 3, 10, 11). Depression has long been 
associated with widespread cognitive deficits (12) which tend to 
worsen over a life span (13).
Specific memory tasks have shown to be sensitive and useful 
in detecting brain dysfunction in the temporal and amygdalo-
hippocampal regions (14), which are consistently reported as 
functionally abnormal in mood disorders and sensation-seeking 
behaviors (15–17).
Importantly, these brain regions are also relevant to the 
neurobiology of substance misuse (18) with similar symptoms 
such as mood, anhedonia, and anxiety associated with drug 
dependence (19). These symptoms may represent a risk factor for 
the development of dependence and also may constitute a specific 
factor by which dependence is maintained, as well as strongly 
associated with major depressive disorder (MDD). However, 
depressive and anxiety symptoms have rarely been investigated 
in opioid dependence within a clinical environment.
Previous studies showed impairments in episodic memory 
(20), visual memory, verbal memory, information processing, 
problem solving (21), and spatial, tactile, and verbal memory 
(2) in heroin-, morphine-, and methadone-dependent 
participants. Curran and colleagues showed that a single dose 
of methadone could negatively impact on episodic memory in 
opiate users (20).
Previously, we have shown that visuospatial memory 
was impaired in chronic heroin and methadone-dependent 
participants, those maintained on methadone as part of opioid 
replacement therapy (ORT), or patients prescribed opioids for 
chronic pain (10). However, to our knowledge, there are no 
previous studies reporting the impact of opioid dependence on 
memory during short-term abstinence from opioids.
Here, we tested the following hypotheses:
 (i) Visuospatial memory impairments are associated with current 
opioid exposure. Conversely, we therefore predicted that 
abstinence would be associated with no significant impairments.
(ii) Cognitive impairments would correlate with mood and 
anxiety ratings. Specifically, we predicted that participants 
with higher depression and anxiety symptoms would have 
greater visuospatial memory impairments.
METHODS
Study approval was granted by the East of Scotland Research 
Ethics Committee (REC reference number: 06/S1401/32) 
and written informed consent obtained from all participants. 
National Health Service (NHS) Scotland Research Governance 
approval was provided by the NHS Fife Research and 
Development Department.
A total of 102 participants were opportunistically enrolled in 
this study with four groups: (i) a stable opioid-dependent group 
receiving methadone maintenance treatment (MMT) (n = 22), 
(ii) a stable opioid-dependent group receiving buprenorphine 
(BMT) (n = 20), (iii) a current abstinent but previously opioid-
dependent group (ABS) (n = 8), and (iv) controls, with no 
history of illicit heroin, methadone, or buprenorphine use 
(n = 52). Patients had a diagnosis of Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV), Opioid 
Dependence and a history of poly-substance misuse with 
heroin as the primary “drug of choice” preceding initiation 
of MMT.
An extensive detailed screening was assessed by two 
clinicians (A.B. or F.D.), which included sociodemographic 
information collection and a semi-structured interview to 
obtain detailed previous histories of drug and alcohol use and 
current opioid dependence status (Table 1 and Supplementary 
Table  1). Clinical histories and diagnoses were obtained 
using the structured Mini International Neuropsychiatric 
Interview (MINI Plus v 5.0) (22) together with a detailed 
review of individual clinical care records. The latter included 
recording the dose of methadone and buprenorphine that 
each participant received at the time of testing. A morphine 
equivalent calculation was performed in accordance to a 
previous publication by Vieweg et al. (23). Each methadone 
dose was multiplied by 20, and each buprenorphine dose was 
multiplied by 12 (23). Ongoing abstinence from illicit drug 
use was also objectively confirmed just prior to scanning with 
a urine drug test (24) using automated enzyme-mediated 
immunoassay to classify any detected drug (25). The Clinical 
Opioid Withdrawal Scale (COWS) was used to quantify 
the level of opioid withdrawal if present (26). Previous care 
records from Addiction Services, psychiatric notes, and 
general practitioners’ records confirmed the absence of 
hepatitis B and C and HIV. Other exclusion criteria included: 
past or current histories of psychotic disorders; post-
traumatic stress disorder (PTSD); antisocial and borderline 
personality disorders; neurological and neurodevelopmental 
disorders; significant head injury; confirmed history of non-
fatal overdose episodes; and co-occurring benzodiazepine, 
stimulant, and/or alcohol dependence.
Current and premorbid intelligence was estimated using the 
Wechsler Abbreviated Scale of Intelligence (WASI) and National 
Adult Reading Test (NART) (27, 28).
Visuospatial Memory Tasks
The Cambridge Neuropsychological Automated Test 
Battery (CANTAB, www.camcog.com) comprises a series of 
computerized memory tasks (29). As previously reported, the 
following tasks have shown specificity to detect impairments 
in visual memory performance [Delayed Matching to Sample 
(DMS), Pattern Recognition Memory (PRM), Spatial Recognition 
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Memory (SRM), and Paired Associate Learning (PAL)] and 
spatial memory performance [Spatial Span Task (SSP) and Spatial 
Working Memory (SWM)] (10).
Depression and Anxiety Rating Scales
Three clinical measures were used to assess the severity of anxiety 
and depressive illness: the Hospital Anxiety and Depression 
Scale (HADS) (30), Beck Depression Inventory (BDI) (23), and 
Inventory of Depressive Symptomatology (IDS): clinician (IDS-
C) and self-report (IDS-SR) (31).
HADS is commonly used to determine depression and 
anxiety. It is a 14-item scale with 7 items that relate to depression 
(HADD) and 7 items to anxiety (HADA) (30). BDI and IDS 
are self-report inventories, and they have been mostly used to 
assess depression and anhedonia (32, 33). BDI demonstrated 
high internal consistency, with an alpha coefficient of 0.82 (34). 
Similarly, IDS demonstrated strong internal consistency, with an 
alpha coefficient of 0.88 (35).
Statistical Analysis
Data meeting assumptions of normality and homogeneity of 
variance were analyzed using analysis of variance (ANOVA) 
(36). All other data were compared using Mann–Whitney test. 
Preliminary analysis of all the experimental and control groups 
separately indicated that the samples did not come from normally 
distributed populations with the same standard deviation. We 
used a post hoc Bonferroni correction in order to control for 
family-wise error for unplanned tests. Mann–Whitney U tests 
established that NART, age, and smoking history needed to be 
used as covariates for hypothesis testing.
A general linear model was performed with “groups” as 
a factor and “visuospatial memory task performances” as 
dependent variables using analysis of covariance (ANCOVA). 
To explore the potential contribution of the impact of depression 
and anxiety scores on memory task performance, we added an 
additional correlational analysis within the ANCOVA.
Data were analyzed using the Statistical Package for the Social 
Science (SPSS) version 24 (SPSS Inc.) in Windows 10 on a PC 
computer. P values < 0.05 were considered significant.
RESULTS
Demographic Characteristics
Demographic and clinical characteristics are presented in 
Table 1. Participants and controls were matched on the basis of 
gender (all males). The MMT, BMT, and ABS groups were older 
TABLE 1 | Demographic, clinical, and substance use history data.
MMT (N = 22) BMT (N = 20) ABS (N = 8) HC (N = 52) Statistics
Number 22 20 8 51
Age in years 33.6. 37.4 37.6 28.0 P < 0.001
MMT, BMT, ABS > HC***
NART 114.3 (5.2) 98.0 (13.5) 106.4 (15.6) 117.5 (6) P < 0.001
BMT, ABS < HC***
HADA 6.0 (4.3) 4.8 (2.7) 4.0 (2.3) 3.5 (3.4) P = 0.04
HADD 4.4 (3.5) 4.4 (2.9) 8.0 (1.5) 1.2 (2.3) P < 0.001
BDI 12.4 (10) 9.9 (6.3) 9.0 (1.8) 3.7 (5.2) P = 0.02
IDS-SR 17.8 (12) 12.6 (6.6) 14.0 (3.2) 7.9 (7.3) P < 0.001
Fagerstrom (total score) 3.4 (2.3) 3.9 (2.3) 3.5 (2.8) ns
OD (methadone or buprenorphine in mg) 73.4 (60.8) 11.0 (6.7) – – P < 0.001
MMT > BMT***
Daily intake expressed as morphine 
equivalent dose in mg
1,835.5 (1,277) 888.0 (533) – – P < 0.001
MMT > BMT***
Age when first used heroin in years 20.2 (4.4) 21.7 (5.4) 20.0 (4.7) – ns
Age when dependent on opioids in years 20.2 (4.4) 23.6 (5.9) 22.9 (8.5) – ns
Age when injecting opioids in years 21.8 (4.2) 24.8 (6) 22.7 (6.9) – ns
Years of opioid use 12.9 (4.4) 13.4 (6.7) 13.4 (7.6) – ns
Age when first used benzodiazepine in 
years
17.2 (5.8) 21.7 (7.7) 15.6 (6.6) P < 0.04
MMT < BMT*
Days of benzodiazepine use in the last 
30 days
– – – – –
Age when first used cocaine in years 17.3 (1) 21.9 (6.6) 18.3 (4.2) – ns
Days of cocaine use in last 30 days – – – – –
Age when first used cannabis in years 13.3 (3.8) 15.8 (5.3) 13.1 (1.2) – ns
Days of cannabis use in last 30 days – – – – –
Age when first used alcohol in years 10.5 (7.9) 15.1 (3) 13.0 (1.9) – 0.04
MMT < BMT*
Days of alcohol use in last 30 days – – – – –
Duration abstinence (days) – – 102.2 (61.3) – –
Values are mean (SD); MMT, methadone maintenance treatment group; BMT, buprenorphine maintenance treatment group; ABS, abstinent group; HC, healthy control group; 
N, total number; HADA, Hospital Anxiety Scale; HADD, Hospital Anxiety Depression; BDI, Beck Depression Inventory; IDS-SR, Inventory of Depressive Symptomatology (self-report); 
NART, National Adult Reading Test; significance * = p = 0.05, *** = p < 0.001; ns, non-significant; mg, milligrams; OD, opioid dose (methadone or buprenorphine).
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than the healthy controls (HCs) (p < 0.001). The HC group had 
higher estimated premorbid IQ (p < 0.001) according to the 
NART than the BMT and ABS groups. The mean morphine 
equivalent daily dose for the MMT group was significantly higher 
than the BMT (p < 0.001). Urine analyses confirmed complete 
absence of recent heroin, amphetamine, benzodiazepine, and 
cocaine prior to neuropsychological testing. The MMT group 
reported they first drank alcohol and consumed benzodiazepine 
approximately 4.5 years prior to the BMT cohort (p < 0.04). 
There were no significant group differences identified on several 
clinical substance history data such as: age when they first used 
heroin (p = 0.6), age when dependent on heroin (p = 0.2), or age 
when injecting opioids (p = 0.3). The MMT, BMT, and ABS were 
well matched with regard to age when they first used cocaine (p = 
0.15) and cannabis (p = 0.13).
Visual Memory
Performance on DMS
There was a significant effect of group on the percentage of 
correct responses for DMS [F(4, 78) = 7.5, p < 0.001]. Post hoc 
Bonferroni comparisons showed that participants from the 
MMT and BMT groups made significantly more errors than the 
ABS and HC groups (p = 0.03 and p < 0.001, respectively). There 
was a significant effect of group on the percentage of correct 
responses for DMS [F(4, 78) = 7.4, p < 0.001]. Post hoc Bonferroni 
comparisons showed that participants from the MMT and BMT 
groups made significantly more errors than the ABS and HC 
groups (p = 0.02 and p < = .001, respectively).
More details are reported in Table 2 and Figure 1.
Performance on PRM, SRM, and PAL
There was a significant effect of group on the percentage of 
correct responses for the PRM task [F(4, 60) = 9.3, p < 0.001] 
and on the mean correct latency for the SRM task [F(4, 60) = 
6.4, p < 0.001]. Similarly, there was a significant effect of group 
on the total adjusted errors on the PAL task [F(4, 75) = 6.1, p < 
0.001] and on PAL first trial memory [F(4, 75) = 5.7, p < 0.001] 
(see Figure 2).
Spatial Memory
Performance on SSP and SWM
There was a significant effect of group on the SSP task (span 
length) [F(4, 75) = 10.5, p < 0.001]. The BMT and ABS groups (a) 
made significantly more errors (between errors) [F(4, 75) = 5, p < 
0.003] and (b) presented with a poorer strategy on the SWM task 
[F(4, 75) = 9.8, p < 0.001].
Depression and Anxiety and Visuospatial 
Memory Performance
Higher HADA anxiety, BDI, and IDS-SR depression scores were 
significantly correlated with PAL (total error adjusted [r (66) = 
0.3, p = 0.01, r (66) = 0.25, p = 0.04, r (64) = 0.3, p < 0.005, 
respectively]). Similarly, higher HADA, BDI, and IDS-SR scores 
were significantly associated with PAL (first trial memory score) 
[r (66) = 0.3, p = 0.007, r (66) = 0.28, p = 0.02, r (64) = 0.4, p = 
0.001, respectively]. DMS (% correct) significantly correlated 
with BDI [r (66) = 0.3, p = 0.01] (see Table 3).
TABLE 2 | Summary of neuropsychological findings for visual and spatial memory.
Memory and learning 
measures
MMT (N = 22) BMT (N = 20) ABS (N = 8) HC (N = 52) Statistics
Visual Memory
DMS
% correct
84.5 (11.6) 80.0 (15) 92.8 (2.1) 92.5 (5.9) P < 0.001,
MMT, BMT < ABS, HC***
DMS
% correct (all delays)
80.2 (14.8) 75.6 (18.5) 91.6 (3.9) 90.7 (7.6) P < 0.001,
MMT, BMT < ABS, HC***
PRM % correct 83.8 (10.1) 80.1 (11.7) 90.2(0.09) 93.2 (4.3) P < 0.001, MMT, BMT < 
ABS, HC***
SRM
mean correct latency
1,997 (377) 2,743 (1,138) 2,150 (454) 1,882 (555) P = 0.001,
BMT > HC***
PAL
total errors adjusted 
125.7 (101) 29.9 (34.6) 11.0 (9) 57.0 (90) P = 0.001,
MMT, BMT > ABS, HC***
PAL first trial memory 
score
8.5 (0.8) 17.9 (4.5) 19.7 (3) 16.4 (9) P = 0.001,
MMT < HC, ABS***
Spatial Memory
SWM between errors 8.8 (15.9)  33.4 (21.4)  22.7 (16.2) 16.6 (21.9) P = 0.003,
BMT > MMT, HC***
SWM strategy  13.1 (14.9)  32.9 (6.9)  31.7 (6) 21.3 (13.4) P < 0.001,
MMT < BMT, ABS***
Values are mean (SD); significance *** = P < 0.001; DMS, Delayed Matching to Sample; PRM, Pattern Recognition Memory, SRM, Spatial Recognition Memory; PAL, Paired 
Associate Learning; SWM, Spatial Working Memory; N, total number.
TABLE 3 | Correlations between depression and anxiety and visuospatial 
performance.
HADA BDI IDS-SR
PAL (total error adjusted) 0.3** 0.25* 0.3**
PAL (first trial memory score) 0.3** 0.28* 0.4***
DMS (% correct) – 0.3** –
* indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.
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DISCUSSION
In this clinically well-characterized study, we have demonstrated 
that memory for visually presented patterns and spatial locations 
was impaired in individuals on ORT. This is consistent with 
previous studies utilizing computerized CANTAB assessment 
with individuals on ORT and HCs. These studies revealed that 
individuals on ORT exhibited impairments in comparison to 
controls on the PRM task (2, 3) and on the PAL task (21). In a 
recent meta-analysis by Baldacchino and colleagues (37), short-
term memory impairments were not present in the abstinence 
cohorts. This is consistent with our present results, as cognitive 
impairments were not present in the abstinent group for both 
visual and spatial memory tasks.
We previously reported that cognitive processes particularly 
associated with the prefrontal cortex are disrupted during 
chronic opioid use but not during abstinence (9). Our results 
could be explained by frontal lobe dysfunction (9, 38–40), which 
can potentially cause impairments on tasks requiring optimal 
memory function with patients receiving ORT. In addition, the 
identified impairments within the opioid-dependent groups on 
ORT point to specific correlations with depression and anxiety, 
particularly with tasks sensitive to the anatomical location of the 
medial temporal lobe.
This is consistent with numerous studies in healthy volunteers 
identifying the medial temporal lobe, such as the hippocampus 
and amygdala, as the area where memory-sensitive tasks are 
encoded (41, 42). Of specific interest, the medial temporal 
lobe regions have been reported 1) as structurally abnormal 
in depressive disorder (16) and 2) as one of the main putative 
candidate regions for both the development and the maintenance 
of dependence (18) and depression (43).
Regarding possible limitations of the present study, we 
recruited only males, so these findings shouldn’t be generalized 
to females (44). Drug use and clinical histories were collected 
based upon self-report, and no blood, hair, or saliva samples 
were available to confirm the accuracy of the information 
given; however, our study did acquire urine drug screen 
analysis to confirm the absence of recent illicit drug use prior 
to every session. Additionally, the present study recruited well-
matched subjects with regard to their previous drug history in 
the experimental groups and excluded regular and dependent 
users of most psychoactive substances, such as alcohol and 
benzodiazepines, as they have been shown to profoundly impact 
neuropsychological performance (18). We couldn’t control the 
effect of nicotine, which may have influenced our results due 
to its known neuropsychological effects on visual and spatial 
memory (45). The burprenorphine group had a significant lower 
morphine equivalent dose than the methadone group, which 
may impact our findings; however, no statistically significant 
correlations were present. Larger studies with long-term 
abstinence are required to fully validate the observed reversibility 
and possible extinction of these impairments.
Clinical Relevance
Patients’ questions about the effects of opioid dependence on 
memory and its impact during abstinence cannot comprehensively 
be answered, due to a current lack of research in this area (10). 
More data are required on the consequences of opioid dependence 
on memory in order to evaluate the acceptability of differential 
treatments, such as methadone and buprenorphine, and perhaps 
maximize abstinence periods (46). Previous studies have indicated 
the importance of detecting memory impairments using highly 
structured and extensive neuropsychological batteries. This is 
further highlighted in the present study, indicating that opioid-
dependent individuals have memory loss in both visual and 
spatial domains. Early identification of memory impairments 
associated with opioid dependence could improve the current 
standard clinical method of assessment. Elucidating the cognitive 
and neural mechanisms responsible for the formation and 
maintenance of opioid-related associative dependence has the 
FIGURE 1 | (A) Delayed Matching to Sample (DMS) task (% correct) box plots: the stable opioid-dependent group receiving methadone maintenance treatment (MMT) and 
that receiving buprenorphine (BMT) made significantly more errors than the abstinent but previously opioid-dependent group (ABS) and healthy controls (HCs) (p < 0.001) 
groups. (B) Pattern Recognition Memory (PRM) task (% correct) box plots: the MMT and BMT made significantly more errors than the ABS and HC (p < 0.001) groups.
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potential for opening up new therapeutic trajectories during both 
the prevention and/or reversal of the significant effects on memory 
and learning, which may be a vulnerability for development and 
maintenance of opioid dependence. Notably, our results highlight 
the possibility that opioid-dependent individuals may benefit 
from focused treatments for depression and anxiety symptoms 
during ORT.
In particular, understanding the underlying neurocognitive 
and brain substrates linked to a dual close relationship between 
comorbid substance misuse and mood states may (a) reveal 
potential new interventions for the treatment of protracted 
opioid dependence and/or relapse (18) and (b) provide the 
required biomarkers to create predictive algorithms to detect 
early dependence and abstinence (6, 7).
CONCLUSION
In summary, our results found that opioid-dependent participants 
exhibited visuospatial memory impairments closely associated with 
depression and anxiety scores. These impairments were not present 
in short-term abstinence, suggesting reversible impairments. 
Further studies need to explore the effect that mood plays in 
cognitive impairments observed in this and other dependent 
populations (e.g. nicotine and alcohol). Indeed, identifying and 
characterizing the visuospatial memory abilities and their potential 
mechanisms of action may be of crucial importance in identifying 
potential common mechanisms controlling the switch from the 
non-dependent to substance-dependent states and ultimately 
achieving abstinence in the opioid-dependent population.
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